160 related articles for article (PubMed ID: 37558183)
1. Health care use and cost of treatment for adolescents and young adults with opioid use disorder.
Orme S; Zarkin GA; Dunlap LJ; Monico LB; Gryczynski J; Fishman MJ; Schwartz RP; O'Grady KE; Mitchell SG
J Subst Use Addict Treat; 2023 Nov; 154():209137. PubMed ID: 37558183
[TBL] [Abstract][Full Text] [Related]
2. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
3. Comparing outcomes of extended-release naltrexone in adolescents and young adults with opioid use disorder.
Mitchell SG; Fletcher JB; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Use Addict Treat; 2024 Aug; 163():209162. PubMed ID: 37730015
[TBL] [Abstract][Full Text] [Related]
4. Healthcare utilization and costs associated with treatment for opioid dependence.
Shah A; Duncan M; Atreja N; Tai KS; Gore M
J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
[TBL] [Abstract][Full Text] [Related]
5. Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
Wenzel K; Selby V; Wildberger J; Lavorato L; Thomas J; Fishman M
J Subst Abuse Treat; 2021 Jun; 125():108306. PubMed ID: 34016297
[TBL] [Abstract][Full Text] [Related]
6. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
Greiner MG; Shulman M; Choo TH; Scodes J; Pavlicova M; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
J Subst Abuse Treat; 2021 Dec; 131():108447. PubMed ID: 34098301
[TBL] [Abstract][Full Text] [Related]
7. Predictors of availability of long-acting medication for opioid use disorder.
Shover CL; Humphreys K
Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
[TBL] [Abstract][Full Text] [Related]
8. Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder.
Monico LB; Fletcher JB; Ross T; Schwartz RP; Fishman MJ; Gryczynski J; Mitchell SG
J Subst Use Addict Treat; 2024 Jul; 162():209334. PubMed ID: 38531508
[TBL] [Abstract][Full Text] [Related]
9. Cost and utilization outcomes of opioid-dependence treatments.
Baser O; Chalk M; Fiellin DA; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
[TBL] [Abstract][Full Text] [Related]
12. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
15. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
[TBL] [Abstract][Full Text] [Related]
18. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
[TBL] [Abstract][Full Text] [Related]
19. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
[TBL] [Abstract][Full Text] [Related]
20. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
